For example, there were no pathogenic or likely pathogenic variants in the MAPT gene to indicate a genetic tauopathy, in genes associated with familial or early onset Alzheimer disease (eg, APP, PSEN1, PSEN2), in TBK1 as a potential promotor of tau hyperphosphorylation in multiple tauopathies, or in TMEM106B, for which the single nucleotide polymorphism rs3173615 has been implicated as a potentially modifying factor in the extent of tauopathy in cases of CTE.16,17,18,19,20 A table of all genes tested and associated results can be reviewed in eTable 1 and eTable 2 in Supplement 1. This evidence concerns the gene MAPT and tauopathy.